# A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

> **NCT03196297** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 36 (actual)

## Conditions studied

- Haemostasis
- Haemophilia A

## Interventions

- **DRUG:** Concizumab
- **DRUG:** Turoctocog alfa

## Key facts

- **NCT ID:** NCT03196297
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-16
- **Primary completion:** 2018-06-22
- **Final completion:** 2020-06-03
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2021-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03196297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03196297, "A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03196297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*